GleamWall
中文EN

IPHA Innate Pharma SA IFRS Annual reports only

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1598599 · Reporting currency EUR · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-67.4%
TTM net income YoY-553.5%
TTM EPS YoY-577.8%
Revenue 3-yr CAGR-6.6%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-256.3%
Net margin-245.9%
FCF margin-36.2%
EBITDA margin-246.4%

Returns

ROE-162.9%
ROA-34.6%
ROIC (approx.)—
Asset turnover0.14x

Leverage & solvency

Liabilities / assets92.0%
Debt / equity0.00x
Current ratio2.60x
Interest coverage-91.12x

Cash quality & payout

Operating cash flow / net income0.14x
Accruals ratio-29.7%
Payout ratio—
Capex / revenue1.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Unit: EUR FY2025*2025-12-31FY2024*2024-12-31FY2023*2023-12-31FY2022*2022-12-31FY2021*2021-12-31
Income statement
Revenue9.01M20.12M61.64M57.67M24.70M
R&D expense43.62M51.98M56.02M51.66M47.00M
SG&A expense19.39M19.72M18.29M22.44M25.52M
Operating income-54.01M-51.58M-12.67M-57.42M-47.83M
Interest expense440,000566,000640,000288,000312,000
Pretax income-49.18M-49.47M-7.57M-57.97M-45.48M
Income tax00000
Net income-49.18M-49.47M-7.57M-58.10M-52.81M
EBITDA-52.62M-49.59M-7.58M-53.00M-43.26M
EPS (basic)-0.55-0.61-0.09-0.73-0.66
EPS (diluted)-0.55-0.61-0.09-0.73-0.66
Balance sheet
Cash & equivalents28.09M66.40M70.61M84.22M103.76M
Short-term investments6.22M14.38M21.85M17.26M16.08M
Receivables12.40M4.97M55.56M38.35M18.42M
Current assets46.71M85.74M148.01M139.83M138.26M
PP&E, netmay include right-of-use assets (IFRS)4.36M5.13M6.32M8.54M10.17M
Intangibles00416,0001.55M44.19M
Total assets62.72M111.06M175.19M199.29M267.50M
Current liabilities36.65M32.98M39.64M41.34M79.89M
Total liabilities84.42M102.22M123.29M145.14M160.06M
Shareholders' equity-21.70M8.83M51.90M54.15M107.44M
Shares outstanding———79.54M—
Cash flow statement
Operating cash flow-52.76M-6.90M-32.56M-19.16M-58.46M
Capital expenditure140,000391,000351,000535,000929,000
Free cash flow-52.90M-7.29M-32.91M-19.69M-59.39M
Investing cash flow7.29M9.20M20.63M1.88M-917,000
Financing cash flow6.07M-6.01M-1.97M-1.83M26.82M
Depreciation & amortization1.38M1.99M5.09M4.42M4.57M
Stock-based compensation2.57M3.94M4.26M4.25M2.62M

Free plan shows the latest 5 periods; Pro shows all 9 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company does not report gross profit in XBRL.

· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-19 06:28.